Quent Capital’s Myriad Genetics MYGN Stock Holding History

Quent Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65	Closed	-$1.51K	–	1341
2023 Q1	$1.51K	Hold	65	–	–	﹤0.01%	1199
2022 Q4	$943	Buy	+65	New	+$1.21K	﹤0.01%	1234

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Quent Capital's MYGN Position: Q2 2023 in Review

Quent Capital sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 65 shares — an estimated $1.51K sold.

Quent Capital first reported a position in MYGN in Q4 2022 and held it in 2 quarters. The position peaked at $1.51K in Q1 2023. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Quent Capital reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Quent Capital sold 65 Myriad Genetics shares in Q2 2023, an estimated $1.51K.
Quent Capital first reported a position in Myriad Genetics in Q4 2022 and held it in 2 quarters.
Quent Capital's Myriad Genetics position peaked at $1.51K in Q1 2023.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.